Kyunghoon Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kyunghoon Lee has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
- Junghan Song
Department of Laboratory Medicine, Seoul National University Bundang Hospital and College of Medicine, Seongnam, Korea
16 shared publications - Joon Hee Lee
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea
11 shared publications - Sail Chun
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
9 shared publications - Sollip Kim
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Institute of Digital Healthcare, University of Ulsan College of Medicine, Seoul, Korea
8 shared publications - Hyung-Doo Park
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
7 shared publications - Sang Hoon Song
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
7 shared publications
Latest Publications
- Open Access
- 8 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1767
Diagnostic Performance and Clinical Utility of Automated Plasma Amyloid-β 1-42/1-40 Assay
Background: Blood-based biomarkers offer an accessible alternative to cerebrospinal fluid or positron emission tomography (PET) imaging for Alzheimer’s disease (AD) screening and diagnosis. This study evaluated the diagnostic performance of the fully automated HISCL plasma Aβ42/40 assay in a real-world clinical setting. Methods: We retrospectively enrolled 127 participants, stratified into cognitively normal (CN), mild cognitive impairment (MCI), AD, and Non-AD subgroups. Plasma Aβ42/40 levels were quantified using the HISCL and Simoa platforms. Additionally, plasma oligomerized Aβ (OAβ), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were measured. Results: The HISCL plasma Aβ42/40 ratio was significantly lower in the AD continuum (MCI + AD) compared to the CN subgroup (p < 0.001). The HISCL assay demonstrated robust diagnostic performance (AUC = 0.747), yielding a comparably higher AUC value compared to the Simoa Aβ42/40 ratio (AUC = 0.687). Although method comparison showed a proportional difference between HISCL and Simoa, the HISCL assay maintained high discriminative capability. Notably, integrating plasma GFAP and NfL with the HISCL Aβ42/40 ratio significantly enhanced the diagnostic accuracy (AUC = 0.823, p = 0.046). Method comparison between heparinized and EDTA plasma in the HISCL assay confirmed assay stability, showing a significant correlation and a regression slope near unity. Conclusions: The HISCL plasma Aβ42/40 assay demonstrates reliable diagnostic performance for identifying AD pathology in clinical practice, showing stability across sample types. Furthermore, its combination with neurodegeneration markers significantly improves predictive accuracy, supporting its utility as a robust screening tool and foundational component of future multimarker diagnostic panels.
- 8 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1767
Open AccessDiagnostic Performance and Clinical Utility of Automated Plasma Amyloid-β 1-42/1-40 Assay
Background: Blood-based biomarkers offer an accessible alternative to cerebrospinal fluid or positron emission tomography (PET) imaging for Alzheimer’s disease (AD) screening and diagnosis. This study evaluated the diagnostic performance of the fully automated HISCL plasma Aβ42/40 assay in a real-world clinical setting. Methods: We retrospectively enrolled 127 participants, stratified into cognitively normal (CN), mild cognitive impairment (MCI), AD, and Non-AD subgroups. Plasma Aβ42/40 levels were quantified using the HISCL and Simoa platforms. Additionally, plasma oligomerized Aβ (OAβ), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were measured. Results: The HISCL plasma Aβ42/40 ratio was significantly lower in the AD continuum (MCI + AD) compared to the CN subgroup (p < 0.001). The HISCL assay demonstrated robust diagnostic performance (AUC = 0.747), yielding a comparably higher AUC value compared to the Simoa Aβ42/40 ratio (AUC = 0.687). Although method comparison showed a proportional difference between HISCL and Simoa, the HISCL assay maintained high discriminative capability. Notably, integrating plasma GFAP and NfL with the HISCL Aβ42/40 ratio significantly enhanced the diagnostic accuracy (AUC = 0.823, p = 0.046). Method comparison between heparinized and EDTA plasma in the HISCL assay confirmed assay stability, showing a significant correlation and a regression slope near unity. Conclusions: The HISCL plasma Aβ42/40 assay demonstrates reliable diagnostic performance for identifying AD pathology in clinical practice, showing stability across sample types. Furthermore, its combination with neurodegeneration markers significantly improves predictive accuracy, supporting its utility as a robust screening tool and foundational component of future multimarker diagnostic panels.
- Open Access
- 4 June 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (5) , 507-523
Essential Data Elements for Laboratory Test Interoperability: An Expert Consensus-Based Framework
Ha Nui Kim, M.D., Min-Sun Kim, M.D., Sollip Kim, M.D., Kuenyoul Park, M.D., Eun-Jung Cho, M.D., Hyejin Ryu, M.D., YeJin Oh, M.D., Shinae Yu, M.D., John Hoon Rim, M.D., Sang-Mi Kim, M.D., Geon Park, M.D., Jaehyeon Lee, M.D., Hyun-Seung Lee, M.D., Hyun-Woo Choi, M.D., You Kyoung Lee, M.D., Jeong Hwan Shin, M.D., Sang-Guk Lee, M.D., Young Kyung Lee, M.D., Jeong-Yeal Ahn, M.D., Sail Chun, M.D., Jungchan Park, M.D., Jong-Yeup Kim, M.D., Hye Hyeon Kim, Ph.D., AeKyung Kwon, M.S., Kyunghoon Lee, M.D., Yeo-Min Yun, M.D., Dongheui An, M.D., Soyoun Shin, M.D., HyunYoung Ji, M.D., On behalf of the Standardization Management Committee of the Laboratory Medicine Foundation, and On behalf of the Clinical Practice Guidelines Committee of the Korean Society for Laboratory Medicine. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0051
- 4 June 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (5) , 507-523
Open AccessEssential Data Elements for Laboratory Test Interoperability: An Expert Consensus-Based Framework
Ha Nui Kim, M.D., Min-Sun Kim, M.D., Sollip Kim, M.D., Kuenyoul Park, M.D., Eun-Jung Cho, M.D., Hyejin Ryu, M.D., YeJin Oh, M.D., Shinae Yu, M.D., John Hoon Rim, M.D., Sang-Mi Kim, M.D., Geon Park, M.D., Jaehyeon Lee, M.D., Hyun-Seung Lee, M.D., Hyun-Woo Choi, M.D., You Kyoung Lee, M.D., Jeong Hwan Shin, M.D., Sang-Guk Lee, M.D., Young Kyung Lee, M.D., Jeong-Yeal Ahn, M.D., Sail Chun, M.D., Jungchan Park, M.D., Jong-Yeup Kim, M.D., Hye Hyeon Kim, Ph.D., AeKyung Kwon, M.S., Kyunghoon Lee, M.D., Yeo-Min Yun, M.D., Dongheui An, M.D., Soyoun Shin, M.D., HyunYoung Ji, M.D., On behalf of the Standardization Management Committee of the Laboratory Medicine Foundation, and On behalf of the Clinical Practice Guidelines Committee of the Korean Society for Laboratory Medicine. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0051
- Open Access
- 28 April 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (9) , 1320
Ensuring HbA1c Accuracy and Variant Detection in Hemoglobin G-Coushatta and Queens Using Variant Mode Analysis
Background/Objectives: Glycated hemoglobin (HbA1c) is widely used to monitor glycemic control, but the accuracy and flag detection rates of HbA1c assays can vary in the presence of Hb variants such as Hb G-Coushatta (Coushatta) and Hb Queens (Queens), which are common in the Korean population. Methods: We evaluated four HbA1c platforms—Arkray ADAMS HA-8190V (HA-8190V) fast/variant modes; Tosoh HLC-723 G11 (G11) standard/variant modes; Bio-Rad D-100 (D-100); Sebia Capillarys 2 Flex Piercing (Capillarys)—using 33 Hb variant samples (26 Coushatta, 7 Queens). The Roche Tina-quant HbA1c Gen. 3 immunoassay was used as the comparative method. With UPLC-MS/MS used as the reference for variant identification, analytical performance was assessed by calculating mean % differences in HbA1c and evaluating Hb variant flag detection rates. Results: The mean % differences in HbA1c compared to the comparative method were −1.5% and −0.9% for Coushatta and Queens, respectively, with HA-8190V variant mode; −28.4% and −17.6% with HA-8190V fast mode; +33.5% and +2.2% with the G11 variant mode; −28.1% and −14.3% with G11 standard mode; −5.9% and −3.2% with D-100; and +1.0% and −6.2% with Capillarys. For flag detection, rates were 100% and 0% with HA-8190V fast mode; 84.6% and 28.6% with G11 standard mode; and 100% and 100% with all other platforms. Conclusions: Coushatta caused severe underestimation in rapid modes, while Queens hindered automated detection. While variant modes significantly improved detection, they showed platform-dependent accuracy. When Hb variant status is unknown, use of the variant mode is recommended to ensure reliable results.
- 28 April 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (9) , 1320
Open AccessEnsuring HbA1c Accuracy and Variant Detection in Hemoglobin G-Coushatta and Queens Using Variant Mode Analysis
Background/Objectives: Glycated hemoglobin (HbA1c) is widely used to monitor glycemic control, but the accuracy and flag detection rates of HbA1c assays can vary in the presence of Hb variants such as Hb G-Coushatta (Coushatta) and Hb Queens (Queens), which are common in the Korean population. Methods: We evaluated four HbA1c platforms—Arkray ADAMS HA-8190V (HA-8190V) fast/variant modes; Tosoh HLC-723 G11 (G11) standard/variant modes; Bio-Rad D-100 (D-100); Sebia Capillarys 2 Flex Piercing (Capillarys)—using 33 Hb variant samples (26 Coushatta, 7 Queens). The Roche Tina-quant HbA1c Gen. 3 immunoassay was used as the comparative method. With UPLC-MS/MS used as the reference for variant identification, analytical performance was assessed by calculating mean % differences in HbA1c and evaluating Hb variant flag detection rates. Results: The mean % differences in HbA1c compared to the comparative method were −1.5% and −0.9% for Coushatta and Queens, respectively, with HA-8190V variant mode; −28.4% and −17.6% with HA-8190V fast mode; +33.5% and +2.2% with the G11 variant mode; −28.1% and −14.3% with G11 standard mode; −5.9% and −3.2% with D-100; and +1.0% and −6.2% with Capillarys. For flag detection, rates were 100% and 0% with HA-8190V fast mode; 84.6% and 28.6% with G11 standard mode; and 100% and 100% with all other platforms. Conclusions: Coushatta caused severe underestimation in rapid modes, while Queens hindered automated detection. While variant modes significantly improved detection, they showed platform-dependent accuracy. When Hb variant status is unknown, use of the variant mode is recommended to ensure reliable results.
- Open Access
- 1 December 2025
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 38, 10-17
Measurement of twenty-one serum steroid profiles by UPLC-MS/MS for the diagnosis and monitoring of congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) represents a group of inherited disorders affecting steroidogenesis. Early and accurate diagnosis is crucial for effective treatment, particularly for preventing adrenal insufficiency and minimizing androgen excess. This study aims to develop and validate an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous quantification of 21 steroid hormones, including 11-oxygenated androgens, which are critical for diagnosing and monitoring various forms of CAH. We utilized a microbore column UPLC combined with hydroxylamine derivatization, which enabled excellent chromatographic separation and enhanced sensitivity of all target compounds. The method was evaluated for precision, linearity, recovery, ion suppression, and carryover according to FDA and CLSI guidelines. Steroid profiles from healthy controls and CAH patients were compared using Mann-Whitney tests. The UPLC-MS/MS method demonstrated excellent precision (2 > 0.99), low limits of detection and quantification, and satisfactory recovery (57–86 % absolute, 99–111 % relative). Our method showed good correlation with proficiency testing group means, although significant negative biases were noted for androstenedione, progesterone, and 11-deoxycortisol. In a clinical setting, significant increases in pregnenolone, progesterone, 17-hydroxyprogesterone, dehydroepiandrosterone, and other key steroids were observed in patients with 21-hydroxylase deficiency, while distinct profiles were identified for patients with 17-hydroxylase deficiency, cytochrome P450 oxidoreductase deficiency, and lipoid CAH. Our UPLC-MS/MS method provides a sensitive and specific tool for the comprehensive profiling of adrenal steroids, offering improved diagnostic accuracy for CAH. Its ability to differentiate between various CAH subtypes highlights its potential clinical utility in both diagnosis and monitoring.
- 1 December 2025
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 38, 10-17
Open AccessMeasurement of twenty-one serum steroid profiles by UPLC-MS/MS for the diagnosis and monitoring of congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) represents a group of inherited disorders affecting steroidogenesis. Early and accurate diagnosis is crucial for effective treatment, particularly for preventing adrenal insufficiency and minimizing androgen excess. This study aims to develop and validate an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous quantification of 21 steroid hormones, including 11-oxygenated androgens, which are critical for diagnosing and monitoring various forms of CAH. We utilized a microbore column UPLC combined with hydroxylamine derivatization, which enabled excellent chromatographic separation and enhanced sensitivity of all target compounds. The method was evaluated for precision, linearity, recovery, ion suppression, and carryover according to FDA and CLSI guidelines. Steroid profiles from healthy controls and CAH patients were compared using Mann-Whitney tests. The UPLC-MS/MS method demonstrated excellent precision (2 > 0.99), low limits of detection and quantification, and satisfactory recovery (57–86 % absolute, 99–111 % relative). Our method showed good correlation with proficiency testing group means, although significant negative biases were noted for androstenedione, progesterone, and 11-deoxycortisol. In a clinical setting, significant increases in pregnenolone, progesterone, 17-hydroxyprogesterone, dehydroepiandrosterone, and other key steroids were observed in patients with 21-hydroxylase deficiency, while distinct profiles were identified for patients with 17-hydroxylase deficiency, cytochrome P450 oxidoreductase deficiency, and lipoid CAH. Our UPLC-MS/MS method provides a sensitive and specific tool for the comprehensive profiling of adrenal steroids, offering improved diagnostic accuracy for CAH. Its ability to differentiate between various CAH subtypes highlights its potential clinical utility in both diagnosis and monitoring.
- 17 September 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (2) , 159-164
Analysis of Pharmacokinetics and Comparison Between One-point Versus Two-point Sampling for Therapeutic Drug Monitoring of Vancomycin in Children
Background: Vancomycin therapeutic drug monitoring (TDM) is essential for optimizing efficacy and minimizing toxicity, particularly in acute kidney injury (AKI). However, recent guidelines favor area under the curve (AUC)-guided dosing over traditional trough monitoring to improve dosing. This study aimed to compare vancomycin TDM strategies in pediatric patients, examine the agreement between 1-point and 2-point sampling methods for AUC estimation, and explore the association between vancomycin exposure and clinical outcomes. Methods: This retrospective cohort study included pediatric patients (2 months to 18 years of age) who underwent vancomycin TDM between 2017 and 2019 (trough-based dosing) and 2020 and 2022 (AUC-based dosing). The pharmacokinetic parameters were estimated using Bayesian software. AKI was defined according to the Kidney Disease: Improving Global Outcomes criteria. Receiver operating characteristic curve analysis was performed to identify the threshold values of AUC and trough concentrations for predicting AKI. Results: A total of 288 patients were included in the study: 164 were from 2017 to 2019 and 124 were from 2020 to 2022, respectively. A comparison of the 1-point and 2-point sampling methods for estimating the AUC showed no significant differences. The incidence of AKI was slightly lower in the 2020–2022 cohort (2.4%) than in the 2017–2019 cohort (6.7%), though the difference was not statistically significant. The AUC threshold for predicting AKI was similar between 1-point and 2-point sampling methods (588–621 mg h/L). Conclusions: AUC-based vancomycin dosing was associated with a reduced incidence of AKI in pediatric patients, without compromising efficacy. Further studies are warranted to refine the exposure targets for bacteremia resolution.
- 17 September 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (2) , 159-164
Analysis of Pharmacokinetics and Comparison Between One-point Versus Two-point Sampling for Therapeutic Drug Monitoring of Vancomycin in Children
Background: Vancomycin therapeutic drug monitoring (TDM) is essential for optimizing efficacy and minimizing toxicity, particularly in acute kidney injury (AKI). However, recent guidelines favor area under the curve (AUC)-guided dosing over traditional trough monitoring to improve dosing. This study aimed to compare vancomycin TDM strategies in pediatric patients, examine the agreement between 1-point and 2-point sampling methods for AUC estimation, and explore the association between vancomycin exposure and clinical outcomes. Methods: This retrospective cohort study included pediatric patients (2 months to 18 years of age) who underwent vancomycin TDM between 2017 and 2019 (trough-based dosing) and 2020 and 2022 (AUC-based dosing). The pharmacokinetic parameters were estimated using Bayesian software. AKI was defined according to the Kidney Disease: Improving Global Outcomes criteria. Receiver operating characteristic curve analysis was performed to identify the threshold values of AUC and trough concentrations for predicting AKI. Results: A total of 288 patients were included in the study: 164 were from 2017 to 2019 and 124 were from 2020 to 2022, respectively. A comparison of the 1-point and 2-point sampling methods for estimating the AUC showed no significant differences. The incidence of AKI was slightly lower in the 2020–2022 cohort (2.4%) than in the 2017–2019 cohort (6.7%), though the difference was not statistically significant. The AUC threshold for predicting AKI was similar between 1-point and 2-point sampling methods (588–621 mg h/L). Conclusions: AUC-based vancomycin dosing was associated with a reduced incidence of AKI in pediatric patients, without compromising efficacy. Further studies are warranted to refine the exposure targets for bacteremia resolution.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (1) , e4
Gaps and Similarities in Research Use LOINC Codes Utilized in Korean University Hospitals: Towards Semantic Interoperability for Patient Care
Park K, et al. J Korean Med Sci. 2024 Oct;40:e4. https://doi.org/10.3346/jkms.2025.40.e4
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (1) , e4
Open AccessGaps and Similarities in Research Use LOINC Codes Utilized in Korean University Hospitals: Towards Semantic Interoperability for Patient Care
Park K, et al. J Korean Med Sci. 2024 Oct;40:e4. https://doi.org/10.3346/jkms.2025.40.e4
- Open Access
- 30 September 2024
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 46 (3) , 145-155
Establishment of Preanalytical Quality Indicators and Current Status of Preanalytical Phase Laboratory Performance Monitoring in the Clinical Laboratories in Korea
Sang-Mi Kim, Kyunghoon Lee, Sollip Kim, Yong-Wha Lee, Sail Chun, and Hyung-Doo Park. Lab Med Qual Assur 2024;46:145-55. https://doi.org/10.15263/jlmqa.2024.46.3.145
- 30 September 2024
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 46 (3) , 145-155
Open AccessEstablishment of Preanalytical Quality Indicators and Current Status of Preanalytical Phase Laboratory Performance Monitoring in the Clinical Laboratories in Korea
Sang-Mi Kim, Kyunghoon Lee, Sollip Kim, Yong-Wha Lee, Sail Chun, and Hyung-Doo Park. Lab Med Qual Assur 2024;46:145-55. https://doi.org/10.15263/jlmqa.2024.46.3.145
- 20 August 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (6) , 518-528
Detecting M-Protein via Mass Spectrometry and Affinity Beads: Enrichment With Mixed Kappa-Lambda Beads Enables Prompt Application in Clinical Laboratories
Background: Detecting monoclonal protein (M-protein), a hallmark of plasma cell disorders, traditionally relies on methods such as protein electrophoresis, immune-electrophosuch as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and electrospray ionization-quadrupole time-of-flight (ESI-qTOF) MS, have emerged as sensitive methods. We explored the M-protein-detection efficacies of different MS techniques. Methods: To isolate immunoglobulin and light chain proteins, six types of beads (IgG, IgA, IgM, kappa, lambda, and mixed kappa and lambda) were used to prepare samples along with CaptureSelect nanobody affinity beads (NBs). After purification, both MALDI-TOF MS and liquid chromatography coupled with Synapt G2 ESI-qTOF high-resolution MS analysis were performed. We purified 25 normal and 25 abnormal IFE samples using NBs and Results: Abnormal samples showed monoclonal peaks, whereas normal samples showed polyclonal peaks. The IgG and mixed kappa and lambda beads showed monoclonal peaks following the use of daratumumab (an IgG/kappa type of monoclonal antibody) with both MALDI-TOF and ESI-qTOF MS analysis. The limits of detection for MALDI-TOF MS and ESIqTOF MS were established as 0.1 g/dL and 0.025 g/dL, respectively. Conclusions: NB-MALDI-TOF and IFE exhibited comparable sensitivity and specificity (92% and 92%, respectively). identified monoclonal peaks with both MALDI-TOF and ESI-qTOF analyses. Qualitative analysis using MALDI-TOF yielded results comparable with that of IFE. NB-MALDI-TOF might be used as an alternative method to replace conventional tests (such as IFE) to detect M-pro
- 20 August 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (6) , 518-528
Detecting M-Protein via Mass Spectrometry and Affinity Beads: Enrichment With Mixed Kappa-Lambda Beads Enables Prompt Application in Clinical Laboratories
Background: Detecting monoclonal protein (M-protein), a hallmark of plasma cell disorders, traditionally relies on methods such as protein electrophoresis, immune-electrophosuch as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and electrospray ionization-quadrupole time-of-flight (ESI-qTOF) MS, have emerged as sensitive methods. We explored the M-protein-detection efficacies of different MS techniques. Methods: To isolate immunoglobulin and light chain proteins, six types of beads (IgG, IgA, IgM, kappa, lambda, and mixed kappa and lambda) were used to prepare samples along with CaptureSelect nanobody affinity beads (NBs). After purification, both MALDI-TOF MS and liquid chromatography coupled with Synapt G2 ESI-qTOF high-resolution MS analysis were performed. We purified 25 normal and 25 abnormal IFE samples using NBs and Results: Abnormal samples showed monoclonal peaks, whereas normal samples showed polyclonal peaks. The IgG and mixed kappa and lambda beads showed monoclonal peaks following the use of daratumumab (an IgG/kappa type of monoclonal antibody) with both MALDI-TOF and ESI-qTOF MS analysis. The limits of detection for MALDI-TOF MS and ESIqTOF MS were established as 0.1 g/dL and 0.025 g/dL, respectively. Conclusions: NB-MALDI-TOF and IFE exhibited comparable sensitivity and specificity (92% and 92%, respectively). identified monoclonal peaks with both MALDI-TOF and ESI-qTOF analyses. Qualitative analysis using MALDI-TOF yielded results comparable with that of IFE. NB-MALDI-TOF might be used as an alternative method to replace conventional tests (such as IFE) to detect M-pro
- Open Access
- 26 June 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (6) , 529-536
Quantitative Evaluation of the Real-World Harmonization Status of Laboratory Test Items Using External Quality Assessment Data
Sollip Kim, M.D., Ph.D., Tae-Dong Jeong, M.D., Ph.D., Kyunghoon Lee, M.D., Ph.D., Jae-Woo Chung, M.D., Ph.D., Eun-Jung Cho, M.D., Ph.D., Seunghoo Lee, M.D., Ph.D., Sail Chun, M.D., Ph.D., Junghan Song, M.D., Ph.D., and Won-Ki Min, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0082
- 26 June 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (6) , 529-536
Open AccessQuantitative Evaluation of the Real-World Harmonization Status of Laboratory Test Items Using External Quality Assessment Data
Sollip Kim, M.D., Ph.D., Tae-Dong Jeong, M.D., Ph.D., Kyunghoon Lee, M.D., Ph.D., Jae-Woo Chung, M.D., Ph.D., Eun-Jung Cho, M.D., Ph.D., Seunghoo Lee, M.D., Ph.D., Sail Chun, M.D., Ph.D., Junghan Song, M.D., Ph.D., and Won-Ki Min, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0082
- Open Access
- 1 April 2024
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 14 (2) , 133-136
A Case of Interference in Serum Creatinine Levels by Post-Operational Cefazolin Administration
Moses Lee, M.D., Ph.D., Joon Hee Lee, M.D., Kyunghoon Lee, M.D., Junghan Song, M.D., Ph.D.. Lab Med Online 2024;14:133-6. https://doi.org/10.47429/lmo.2024.14.2.133
- 1 April 2024
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 14 (2) , 133-136
Open AccessA Case of Interference in Serum Creatinine Levels by Post-Operational Cefazolin Administration
Moses Lee, M.D., Ph.D., Joon Hee Lee, M.D., Kyunghoon Lee, M.D., Junghan Song, M.D., Ph.D.. Lab Med Online 2024;14:133-6. https://doi.org/10.47429/lmo.2024.14.2.133